North America Diabetic Foot Ulcer Treatment Market Rises at 5.74% CAGR by 2034

The North America diabetic foot ulcer treatment market size is calculated at USD 1.34 billion in 2025 and is expected to reach soar USD 2.22 billion by 2034, growing at a CAGR of 5.74% for the forecasted period.

Ottawa, Sept. 15, 2025 (GLOBE NEWSWIRE) -- The North America diabetic foot ulcer treatment market size was valued at USD 1.27 billion in 2024 and is predicted to reach around USD 2.22 billion by 2034, rising at a 5.74% CAGR, a study published by Towards Healthcare a sister firm of Precedence Research. Continuous R&D activities and the accelerating cases of diabetes are expanding the global market development.

The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/5426

Key Takeaways

The United States (U.S.) led the North America diabetic foot ulcer treatment market in 2024.
Canada is expected to grow at a significant CAGR during 2025-2034.
By treatment, the biologics segment dominated the market in 2024.
By treatment, the therapy devices segment is expected to grow fastest in the predicted timeframe.
By ulcer type, the neuro-ischemic ulcer segment was dominant in the market in 2024 and is expected to witness rapid expansion during the forecast period.
By end-use, the homecare segment registered dominance in the market in 2024.

Market Overview & Potential

The overall North America diabetic foot ulcer treatment market is fostering many standard treatments, including debridement, wound dressings, offloading, and infection control, coupled with new approaches, like Negative Pressure Wound Therapy (NPWT) for complex wounds. In 2025, the market is promoting novel advances in R&D areas, particularly Hyperbaric Oxygen Therapy, low-dose shockwave therapy, and topical applications of substances, such as phenytoin and honey, are also applied to enhance healing.

What are the Major Growth Drivers in the Market Expansion?

North America’s aging population, which is highly prone to diabetes, peripheral neuropathy, and peripheral artery disease, is transforming the North America diabetic foot ulcer treatment market growth. Along with this, another crucial driver is a strong, well-established healthcare system that further assists in a broader range of adoption and integration of innovative and advanced DFU therapies. Consequently, a rise in numerous alliances among healthcare services, technology providers, and consulting firms is fueling the huge demand for advanced diabetic foot ulcer treatment.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

What are the Key Trends in the Respective Market?

Involvement of heavy R&D investment in diabetes and other collaborations is acting as a major growth factor in the North America diabetic foot ulcer treatment market expansion.

In June 2025, Portage Biotech Inc., an immuno-oncology company, entered into a Subscription Agreement with Compedica Holdings Limited to expand the development and commercialization of Compedica’s medical device technology, mainly the OptiPulse active therapy system, evolved to treat Diabetic Foot Ulcers (DFUs).
In March 2025, Podimetrics and Alivi Health entered into a new partnership to support diabetic foot health.
In January 2025, Siren secured $9.5 million, with an $8 million check from lead investor Mölnlycke Health Care to further the development and adoption of its diabetic foot ulcer (DFU) prevention product.

What is the Arising Challenge in the Market?

The North America diabetic foot ulcer treatment market is facing a crucial hurdle in its growth, such as restrictions in time during clinical encounters, concerns with health insurance coverage for routine care and drugs, health literacy between patients, and the stigma linked with diabetes and foot ulcers, all of which create a vital barrier in comprehensive care.

Regional Analysis

How did the US hold a Major Share of the Market in 2024?

In 2024, the US accounted for the largest share of the market, and in the coming era, Canada is estimated to show a notable growth in the North America diabetic foot ulcer treatment market. Mainly, the US encompasses wound cleansing, removal of necrotic (dead) tissue, and the application of proper dressings, like occlusive or semi-occlusive dressings for shallow ulcers. Alongside the exploration of innovative materials, specifically Granexin®, a gel-based biomaterial that targets cell proliferation to optimize reepithelialization. While Canada’s execution of united care pathways, for e.g., the one in Alberta, aims to standardize and boost early screening, care for low-risk patients, and provide access to specialist services for complex conditions.

For instance,

In April 2025, HealthMed and Podimetrics partnered to support diabetes patients in managing foot health and mobility, which will be incorporated into HealthMed's employee-focused portfolio of benefits.

Diabetic Foot Ulcer Treatment Market Size and Growth

The global diabetic foot ulcer treatment market size was estimated at US$ 5.20 billion in 2023 and is projected to grow to US$ 9.84 billion by 2034, rising at a compound annual growth rate (CAGR) of 6.04% from 2024 to 2034.

Become a valued research partner with us - https://www.towardshealthcare.com/schedule-meeting

Segmental Insights

By treatment analysis

Why did the Biologics Segment Lead the Market in 2024?

The biologics segment held a major share of the North America diabetic foot ulcer treatment market in 2024. Advancing therapies, such as boosting skin substitutes and stem cell therapies to expand tissue regeneration, are propelling the development. Whereas, the era is developing smart dressings and hydrogels for controlled delivery, alongside promoting exosome-based therapies derived from MSCs. Other evolving solutions comprise human skin equivalents, like Apligraf and Dermagraft, and therapies targeting oxidative stress, such as natural biologics, are influencing the overall innovations.

On the other hand, the therapy devices segment is anticipated to witness the fastest growth during 2025-2034. This segment consists of a novel dressing approach that releases nitric oxide, with its vasodilatory and antimicrobial properties, ultimately supporting wound blood flow and fighting infection. Another catalyst is Photobiomodulation (PBM) is a low-level light therapy (LLLT) utilizing LEDs is an efficient and portable method to help angiogenesis and tissue repair. Including Transcutaneous Electrical Nerve Stimulation (TENS) therapy employing electrical currents to stimulate nerves, with its advantages for patients with DFUs and associated neuropathy.

By ulcer type analysis

How did the Neuro-Ischemic Ulcer Segment Dominate the Market in 2024?

The neuro-ischemic ulcer segment held a dominant share of the market in 2024 and will grow rapidly in the North America diabetic foot ulcer treatment market. Rising emphasis on healing rates by highlighting both neurological deficits and poor blood flow through multidisciplinary treatment, like revascularization for severe instances, is fueling the overall market progress. Ongoing innovations in regenerative therapies, especially Regenerating agents (RGTAs), ON101 cream, and nitric oxide-generating dressings, are transforming the robust solutions for DFU. The use of platelet-rich fibrin (PRF) and new topical treatments, such as sucrose octasulfate-impregnated dressings, is assisting in to recovery of neuro-ischemic ulcer.

By end-use analysis

What Made the Homecare Segment Dominant in the Market in 2024?

The homecare segment held the biggest share of the North America diabetic foot ulcer treatment market in 2024. Primarily, this segment comprises daily foot checking, moisturizing feet, wearing proper footwear, and checking blood sugar level. Moreover, the application of offloading devices, like Total contact casts (TCCs) and specialized footwear, involves redistributing pressure away from the wound site, preventing further damage and boosting healing. Effectiveness of Negative-Pressure Wound Therapy (NPWT), expanding the vacuum pressure to improve the healing process at home.

Get the latest insights on healthcare industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership

Recent Developments

In September 2025, RION, a clinical-stage regenerative medicine company and global leader in exosome-based therapeutics, introduced INTENT Biologics, a new independent biotechnology company exploring first-in-class exosome therapies for Inflammation & Immunology (I&I).
In January 2025, BioStem Technologies, Inc., a leading MedTech company, launched the BR-AM-DFU (BioREtain^® Amniotic Membrane - Diabetic Foot Ulcers) clinical trial to assess Vendaje^® versus standard of care for patients suffering from non-healing diabetic foot ulcers.
In August 2024, IPCA Laboratories Ltd launched Diulcus®, a new product emphasis on addressing the risks of Diabetic Foot Ulcer (DFU) in the Indian market.

North America Diabetic Foot Ulcer Treatment Market Key Players

3M
Acelity L.P. Inc.
Adlore Inc.
BioStem Technologies
Cardinal Health
Convatec Inc.
DeCell Technologies
Integra Lifesciences
Medline Industries
Microbion Group
MicuRx Pharmaceuticals Inc.
Organogenesis Holdings
StimLabs

Browse More Insights of Towards Healthcare:

The global heartworm treatment products market was valued at USD 1.45 billion in 2024, increased to USD 1.55 billion in 2025, and is projected to reach USD 2.85 billion by 2034, expanding at a CAGR of 7.04% between 2025 and 2034.

The global hematologic malignancies treatment market stood at USD 67.32 billion in 2024 and is expected to grow steadily to USD 72.49 billion in 2025 and further to USD 139.13 billion by 2034, registering a CAGR of 7.61% during the forecast period.

The global progressive pulmonary fibrosis (PPF) treatment market size was USD 0.6 billion in 2024, rose to USD 0.69 billion in 2025, and is forecasted to reach around USD 2.45 billion by 2034, expanding at a CAGR of 15.21% between 2025 and 2034.

The global cocaine intoxication treatment market was valued at USD 17.91 million in 2024, grew to USD 19 million in 2025, and is anticipated to reach USD 32.15 million by 2034, advancing at a CAGR of 6.05% from 2025 to 2034.

The global strongyloidiasis treatment market size was estimated at USD 1.1 billion in 2024, grew to USD 1.15 billion in 2025, and is projected to hit USD 1.72 billion by 2034, recording a CAGR of 4.5% between 2025 and 2034.

The global bronchitis treatment market was valued at USD 6.85 billion in 2024, increased to USD 7.21 billion in 2025, and is set to reach USD 11.45 billion by 2034, growing at a CAGR of 5.28% from 2025 to 2034.

The global Sandhoff disease treatment market accounted for USD 260 million in 2024, expanded to USD 274.95 million in 2025, and is projected to reach USD 456.42 million by 2034, with a CAGR of 5.75% during the forecast period.

The global optic nerve atrophy treatment market was valued at USD 2.53 billion in 2024, grew to USD 2.75 billion in 2025, and is forecasted to hit USD 5.87 billion by 2034, advancing at a CAGR of 8.85% between 2025 and 2034.

The global chronic disease treatment market size was USD 8.37 billion in 2024, increased to USD 9.74 billion in 2025, and is expected to surge to USD 38.02 billion by 2034, registering a robust CAGR of 16.34% throughout the forecast period.

The global rare disease treatment market reached USD 195.21 billion in 2024, expanded to USD 217.93 billion in 2025, and is projected to attain USD 587.08 billion by 2034, growing at a CAGR of 11.64% between 2025 and 2034.

Segments Covered in The Report

By Treatment

Biologics
- Growth Factors
- Skin Grafts
Therapy Devices
- Negative Pressure Wound Therapy
- Ultrasound Therapy
Wound Care Dressings
- Alginate Dressings
- Hydrofiber Dressings
- Foam Dressings
- Film Dressings
- Hydrocolloid Dressings
- Surgical Dressings
- Hydrogel Dressings
Antibiotic Medications
Others

By Ulcer Type

Neuro-Ischemic Ulcers
Neuropathic Ulcers
Ischemic Ulcers

By End-Use

Homecare
Hospitals
Ambulatory Imaging Center

By Region

North America
- U.S.
- Canada

Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/price/5426

Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard: https://www.towardshealthcare.com/access-dashboard

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Europe Region: +44 778 256 0738

North America Region: +1 8044 4193 44

APAC Region: +91 9356 9282 04

Web: https://www.towardshealthcare.com

Our Trusted Data Partners

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.